Colo-rectal CancerTalin-1/CR-1NCT07414082
Serum Talin-1 and Cripto-1 in Colorectal Cancer
A study testing Serum level of Human Talin-1 and Serum level of Human Cripto-1 in people with Colo-rectal Cancer, run by Assiut University at 1 site in Egypt.
Trial summary
The goals of this study are To evaluate the clinical utility of Talin-1 and Cripto-1 measurement in colorectal cancer patients in comparison with healthy controls. To Compare the diagnostic significance of serum Talin-1 and Cripto-1 with traditional serum biomarker CEA Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Colo-rectal Cancer
- What is being tested?
- Serum level of Human Talin-1 and Serum level of Human Cripto-1
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteEgypt
- Study dates
- 30 Mar 2026to 31 Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age >18 years Old.
- Patients of both sexes who met the clinical diagnostic criteria of colorectal cancer (change in bowel habit, absolute or recurrent constipation, rectal bleeding, significant weight loss or intestinal obstruction)
- Patients diagnosed with colorectal cancer by imaging and histopathology
Who cannot join
- Age <18 years old.
- Patients with past history of chemotherapy or surgical excision of tumor
- Patients with familial adenomatous polyposis
- Patients with hereditary non-polyposis colorectal cancer
- Patients with inflammatory bowel disease
- patients with other types of tumors
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Sherouk Ahmed Sayed, Assistant lecturer contact
Egypt1 site
Assuit University Hospital
Asyut, Asyut Governorate, 17777
Sherouk Ahmed, 01123232632
About this study
Official title: Evaluating Serum Talin-1 and Cripto-1 as Diagnostic Biomarkers in Colorectal Cancer
The goals of this study are
- To evaluate the clinical utility of Talin-1 and Cripto-1 measurement in colorectal cancer patients in comparison with healthy controls.
- To Compare the diagnostic significance of serum Talin-1 and Cripto-1 with traditional serum biomarker CEA
Read the detailed description
Colorectal cancer (CRC) is a major global health concern, ranking as the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths. CRC is a malignancy predominantly affecting older adults, posing significant threats to their health and creating formidable challenges for healthcare systems.
Compared to younger patients, elderly CRC often presents with atypical symptoms. In some cases, the initial manifestations are not hematochezia or abdominal pain but anaemia and weight loss, leading to frequent late-stage (Stage IV) diagnoses, which complicates treatment.
Talin-1 serves as a crucial element within the multiprotein adhesion complexes that facilitate processes such as cell migration, adhesion, and integrin signalling. It has been demonstrated that the level of Talin-1 in the serum of colon cancer patients was significantly higher than that of healthy controls. Talin-1 may be a valuable biomarker for colon cancer, which may be essential for the early detection, especially in combination with other markers in population screenings that are currently used to detect the colon cancer.
Human Cripto-1 (CR-1) is an embryonic gene, belonging to the EGF-CFC gene family, which is necessary for promoting early stages of embryonic development. CR-1 is a good example of a multifaceted embryonic protein that is re-expressed in most human tumors, particularly colorectal tumor, but not detected in normal adult human tissues. García-Sanmartín et al. showed that Cripto-1 expression was significantly correlated with worse prognosis in CRC, and was an independent prognostic factor.
- Conditions
- Colo-rectal Cancer
- Being tested
- Serum level of Human Talin-1, Serum level of Human Cripto-1
- Medical subject headings
- Colonic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Serum level of Human Talin-1Diagnostic test
To evaluate the clinical utility of Talin-1 measurement in colorectal cancer patients in comparison with healthy controls.
Serum level of Human Cripto-1Diagnostic test
To evaluate the clinical utility of Cripto-1 measurement in colorectal cancer patients in comparison with healthy controls.
| Study group | Role | What they receive |
|---|---|---|
| Group(1) | Experimental | Not described Receives: Diagnostic Test: Serum level of Human Talin-1; Diagnostic Test: Serum level of Human Cripto-1 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Serum Talin-1 measurement in colorectal cancer patients
measuring serum level of talin-1 in colorectal cancer patient to compare its level with healthy control
Measured: From enrollment up to one week
Secondary outcomes (1)
Serum Cripto-1 measurement in colorectal cancer patients
Measured: From enrollment up to one week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2026
- Study start30 Mar 2026 (estimated)
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colo-rectal CancerStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shrook S. Ahmed, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07414082
- Sponsor's protocol ID
- SHROOK
- Acronym
- Talin-1/CR-1
- Status last verified
- Jan 2026
- First submitted
- 24 Jan 2026
- Last updated
- 17 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating Serum Talin-1 and Cripto-1 as Diagnostic Biomarkers in Colorectal Cancer
- ClinicalTrials.gov ID
- NCT07414082
- Acronym / sponsor ID
- Talin-1/CR-1 / SHROOK
- Conditions
- Colo-rectal Cancer
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 30 Mar 2026 (estimated)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 17 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goals of this study are
- To evaluate the clinical utility of Talin-1 and Cripto-1 measurement in colorectal cancer patients in comparison with healthy controls.
- To Compare the diagnostic significance of serum Talin-1 and Cripto-1 with traditional serum biomarker CEA
Detailed description
Colorectal cancer (CRC) is a major global health concern, ranking as the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths. CRC is a malignancy predominantly affecting older adults, posing significant threats to their health and creating formidable challenges for healthcare systems.
Compared to younger patients, elderly CRC often presents with atypical symptoms. In some cases, the initial manifestations are not hematochezia or abdominal pain but anaemia and weight loss, leading to frequent late-stage (Stage IV) diagnoses, which complicates treatment.
Talin-1 serves as a crucial element within the multiprotein adhesion complexes that facilitate processes such as cell migration, adhesion, and integrin signalling. It has been demonstrated that the level of Talin-1 in the serum of colon cancer patients was significantly higher than that of healthy controls. Talin-1 may be a valuable biomarker for colon cancer, which may be essential for the early detection, especially in combination with other markers in population screenings that are currently used to detect the colon cancer.
Human Cripto-1 (CR-1) is an embryonic gene, belonging to the EGF-CFC gene family, which is necessary for promoting early stages of embryonic development. CR-1 is a good example of a multifaceted embryonic protein that is re-expressed in most human tumors, particularly colorectal tumor, but not detected in normal adult human tissues. García-Sanmartín et al. showed that Cripto-1 expression was significantly correlated with worse prognosis in CRC, and was an independent prognostic factor.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Group(1) | Experimental | Diagnostic Test: Serum level of Human Talin-1, Diagnostic Test: Serum level of Human Cripto-1 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age >18 years Old.
- Patients of both sexes who met the clinical diagnostic criteria of colorectal cancer (change in bowel habit, absolute or recurrent constipation, rectal bleeding, significant weight loss or intestinal obstruction)
- Patients diagnosed with colorectal cancer by imaging and histopathology
Key exclusion criteria (6 listed)
- Age <18 years old.
- Patients with past history of chemotherapy or surgical excision of tumor
- Patients with familial adenomatous polyposis
- Patients with hereditary non-polyposis colorectal cancer
- Patients with inflammatory bowel disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Serum level of Human Talin-1To evaluate the clinical utility of Talin-1 measurement in colorectal cancer patients in comparison with healthy controls. | Diagnostic test | Group(1) |
| Serum level of Human Cripto-1To evaluate the clinical utility of Cripto-1 measurement in colorectal cancer patients in comparison with healthy controls. | Diagnostic test | Group(1) |
Primary outcome
Serum Talin-1 measurement in colorectal cancer patients
Time frame: From enrollment up to one week
measuring serum level of talin-1 in colorectal cancer patient to compare its level with healthy control
1 secondary outcome
Serum Cripto-1 measurement in colorectal cancer patients
Time frame: From enrollment up to one week
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2026.
Related trials for Colo-rectal Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 1/2
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Advanced Solid Tumors, Metastatic Solid Tumors
Active, not recruitingPhase 2/3
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
RecruitingObservational study
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Brain Cancer, Breast Cancer
RecruitingPhase 1
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ovarian Neoplasms, Endometrial Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sherouk Ahmed Sayed, Assistant lecturer contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Serum level of Human Talin-1 and Serum level of Human Cripto-1 in people with Colo-rectal Cancer, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sherouk Ahmed Sayed, Assistant lecturer (+201123232632 ext. +201009922949, shrookabozaid@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Serum Talin-1 measurement in colorectal cancer patients (time frame: From enrollment up to one week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2026.